Released May 5, 2026, before the open
10-Q filed May 5, 2026, 35 days after period end · 0001193125-26-205003
Q1 2026 · 10-Q
Revenue$196.71M$196.71M +1.6% vs Q1 2025−10.6% vs Q4 2025
Net Income-$20.91M-$20.91M N/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.52-$0.52 N/M vs Q1 2025no prior Q4 2025 on file
Gross Profit$139,546,000+14.7%
Operating Income-$14,436,000N/M
Operating Cash Flow-$17,610,000N/M
Free Cash Flowderived-$28,271,000N/M
Margins · derived
Gross margin70.9%+8.1 pt vs Q1 2025
Operating margin-7.3%+17.9 pt vs Q1 2025
Net margin-10.6%+16.8 pt vs Q1 2025
What the release said
The release
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $196.71M | $193.65M | $188.61M | $175.20M |
| Net Income | -$20.91M | -$53.09M | -$36.02M | -$60.94M |
| EPS Diluted | -$0.52 | -$1.35 | -$0.95 | -$1.71 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR